As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Injectables for type 2 diabetes and weight loss could soon be a thing of the ... 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14.

However, many people are increasingly turning to innovative supplements that promise to support their weight loss journey naturally. One such groundbreaking option is Slimlex GLP-1 Capsules ...

The unique advantage of Slimlex over traditional weight loss solutions, such as Ozempic or Wegovy, lies in its formulation, which comprises all-natural ingredients. Slimlex GLP-1 Capsules utilize ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...